Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Mayo Clin Proc. 2020 Jan;95(1):124–133. doi: 10.1016/j.mayocp.2019.07.008

Table 3.

Baseline Characteristics of DM and non DM Groups with no Diastolic Dysfunction

Variable Non-DM DM P-value
(N=128) (N=64)
Age at Exam (years) 62.6 ± 9.2 62.7± 9.2 .94
Gender, n (%) 48 (38%) 24 (38%) --
BMI of Patient 28.8± 4.9 30.4± 5.9 .04
BMI>30, n (%) 48 (38%) 29 (45%) .30
Waist>102M, 88F, n(%) 50 (39%) 31 (48%) .21
Metabolic Syndrome, n (%) 29 (23%) 35 (56%) <.001
Verified Hypertension, n(%) 54 (42%) 29 (45%) .68
CAD (%) 33 (26%) 21 (33%) .31
HF (n%) 0 (0%) 0 (0%) --
MI n,(%) 10 (8%) 10 (16%) .09
Atrial Fib/Flutter n,(%) 4 (3%) 5 (8%) .15
Stroke n,(%) 0 (0%) 0 (0%) --
Beta Blocker, n(%) 26 (22%) 19 (31%) .17
Calcium Channel Blocker, n(%) 17 (14%) 5 (8%) .24
ACE Inhibitor, n(%) 10 (8%) 17 (28%) <.001
Antilipemic Therapy, n(%) 27 (23%) 25 (41%) .01
Total Cholesterol (mg/dL) 201.7 ± 38.1 188.9 ± 40.8 .04
LDL Cholesterol (mg/dL) 126.8 ± 33.3 114.9 ± 34.2 .02
Triglycerides (mg/dL) 153.5 ± 87.9 180.4 ± 117.3 .08
HDL (mg/dL) <40M, <50F, n(%) 64 (51%) 46 (73%) .004
NT-proBNP (pg/mL), median (Q1, Q3) 76.9 (32.3, 153.6) 61.7 (15.6, 126) 0.85
Aldosterone (pg/ml), median (Q1, Q3) 4.8 (2.9, 9.2) 5.1 (2.5, 8.3) 0.64
Insulin (uU/mL), median (Q1, Q3) 5.6 (3.6, 8.1) 8.3 (5, 15) <.001
Creatinine (mg/dL), median (Q1, Q3) 0.9 (0.8, 1) 0.9 (0.7, 1) .63
SBP (mmHg) 131.7 ± 19 134 ± 17 .43
DBP (mmHg) 73.6 ± 10.2 72.8 ± 7.3 .59
Serum Glucose (mg/dL), median (Q1, Q3) 94 (89, 100) 129 (111, 158) <.001
a

ACE angiotensin-converting enzyme, BMI body mass index, CAD coronary artery disease, HF heart failure, DBP diastolic blood pressure, MI myocardial infarction, HDL high-density lipoprotein, LDL low-density lipoprotein, NT-proBNP n-terminal pro hormone b-type natriuretic peptide, SBP systolic blood pressure

b

dL deciliter, mg milligram, mmHg millimeters of mercury, Pg picogram, uU international unit